Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia

Απλή σελίδα τεκμηρίου
dc.contributor.authorPavlidis, A. N.en
dc.contributor.authorKalef-Ezra, J.en
dc.contributor.authorBourantas, L. C.en
dc.contributor.authorLambrou, A.en
dc.contributor.authorMavridis, A.en
dc.date.accessioned2015-11-24T18:52:01Z
dc.date.available2015-11-24T18:52:01Z
dc.identifier.issn0393-6155-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18342
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subject*Blood Sedimentationen
dc.subjectC-Reactive Protein/*analysisen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell/*blood/mortalityen
dc.subjectLife Tablesen
dc.subjectLymphoma, Non-Hodgkin/*blood/mortality/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Proteins/*blooden
dc.subjectPrognosisen
dc.subjectReceptors, Interleukin-2/*analysisen
dc.subjectSurvival Analysisen
dc.subjectTumor Markers, Biological/*blooden
dc.subjectbeta 2-Microglobulin/*analysisen
dc.titleSerum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemiaen
heal.abstractThe levels of soluble interleukin-2 receptors (sIL-2R), beta-2 microglobulin (beta-2M), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured in the serum of 50 previously untreated patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) as well as in 25 age and sex-matched normal controls. Compared to normal controls, mean serum levels of sIL-2R and beta-2M were significantly increased in both NHL and CLL (p < 0.001) while the increase in ESR and CRP was less marked (p < 0.01 and p < 0.05, respectively). Comparison of these tumor markers with histologic grading showed statistically significant differences only for CRP between low, intermediate and high-grade lymphomas (p < 0.001 and p < 0.05). More advanced stages exhibited higher mean values of all serum markers than early stages (p < 0.001 for sIL-2R, beta-2M and ESR and p < 0.05 for CRP). An association with the presence of b-symptoms was observed only for sIL-2R (p < 0.05). In addition, sIL-2R as well as beta-2M were able to predict time to progression in patients with diffuse large-cell lymphomas. We conclude that of the four tumor markers tested sIL-2R and beta-2M more frequently showed increased serum levels and were associated with clinical stage and/or presence of b-symptoms. Both sIL-2R and beta-2M were also found to have prognostic significance for survival.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8496627-
heal.journalNameInt J Biol Markersen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1993-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ